)
Edge23 Jan 2026
Death, Taxes, and Garbage: The Story of WM
How Waste Management turned garbage into one of America's most stable business models through landfills, regulation, and nationwide scale.
EyePoint Pharmaceuticals
EyePoint Pharmaceuticals (EYPT) investor relations material
EyePoint Pharmaceuticals 44th Annual J.P. Morgan Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.44th Annual J.P. Morgan Healthcare Conference summary13 Jan, 2026
Key product and clinical development updates
DURAVYU, a sustained-release, multi-mechanism TKI for retinal diseases, is in phase III trials for wet AMD and DME, with topline wet AMD data expected mid-2026 and DME enrollment beginning Q1 2026.
The proprietary Durasert delivery system offers ≥6 months of sustained drug release, room temperature storage, and is used in four FDA-approved products.
DURAVYU blocks VEGF, PDGF, and IL-6, with robust efficacy and safety demonstrated in multiple trials, including no severe adverse events in over 190 patients.
Phase II and III trials show non-inferiority to Eylea/aflibercept, significant reduction in treatment burden, and robust safety.
DME program leverages positive Phase 2 VERONA data, with global phase III trials (COMO and CAPRI) designed for rapid enrollment and regulatory success.
Market landscape and commercial strategy
Market need remains for longer-lasting therapies, as current drugs require frequent injections and many patients cannot extend intervals beyond eight weeks.
DURAVYU's multi-MOA and six-month dosing interval are expected to drive adoption, especially among retina specialists seeking to reduce patient load.
Educational efforts will focus on integrating DURAVYU into existing treatment paradigms, emphasizing its compatibility with anti-VEGF therapies.
DURAVYU is positioned to capture meaningful share in the $15B anti-VEGF market, with a best-in-class profile and first-mover advantage in key indications.
Competitive differentiation is based on trial design, multi-MOA, and robust safety/efficacy data compared to other TKI programs.
Manufacturing and commercialization
Commercial manufacturing scale-up is underway in a new 41,000 sq ft Northbridge, MA facility built to FDA and EMA standards, supporting NDA filing and launch.
Registration batches are underway, and the facility is designed for scalability and regulatory compliance.
Commercial supply buildout is included in financial projections, with facility readiness for initial launch.
What market share impact from DURAVYU's MOA?
Why are DME trials smaller than wet AMD trials?
Cash runway beyond Q4 2027: funding strategy?
DURAVYU's unique advantage in DME
Strategy for DURAVYU market adoption
Commercial manufacturing scale-up capacity
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next EyePoint Pharmaceuticals earnings date
Q4 20252 Mar, 2026
EyePoint Pharmaceuticals
Next EyePoint Pharmaceuticals earnings date
Q4 20252 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
EyePoint Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing ophthalmic therapies. The company specializes in sustained-release drug delivery technologies to address serious eye diseases, including conditions affecting the retina and anterior segment of the eye. EyePoint’s product portfolio includes treatments for inflammation and other ocular disorders, and it supports both commercialized products and clinical development programs. The company is headquartered in Watertown, Massachusetts, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage